BofA lowered the firm’s price target on Tyra Biosciences (TYRA) to $29 from $31 and keeps a Buy rating on the shares. Tyra had “an uneventful” Q3 update, which is “unlikely to reverse sentiment that has weighed on the story of late,” the analyst tells investors. While the firm understands the broader safety concerns, it maintains its view that FDA’s approval of the IND for pediatric achondroplasia was “a clear signal of support for the lower doses,” the analyst tells investors. The firm continues to see reasons to like the story with recent weakness “offering a particularly compelling entry point,” the analyst added.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TYRA:
- Tyra Biosciences price target lowered to $30 from $32 at H.C. Wainwright
- Tyra Biosciences’ Q3 2024: Clinical Progress and Financial Resilience
- Tyra Biosciences reports Q3 EPS (41c), consensus (40c)
- 3 Best Stocks to Buy Now, 10/28/2024, According to Top Analysts
- Tyra Biosciences granted IND clearance from FDA for Phase 2 study of Tyra-300
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue